Chordate CEO in new interview: “The majority of global players supply their technology portfolio through acquisitions”

Chordate Medical’s CEO, Anders Weilandt, discusses the company’s successes in its focus markets, the exit strategy, and the rights issue in a new interview with Direkt Studios. The subscription period for the rights issue runs from February 2 to February 16.

“We have a strategy that involves firstly building the technology, and that’s done. Secondly, the technology needs to be protected, and we’ve achieved that through patents. Then we have established scientific evidence in several steps—that process is not entirely done, but sufficiently. And now, finally, we will demonstrate that this can be sold and that there is a buying market for it. So that’s our entire focus […] Major global medtech and pharmaceutical players primarily supply their technology portfolio through acquisitions, and we want to be such an example; that’s the whole idea,” says Anders Weilandt in the interview.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy